Reviews |
From the Division of Molecular and Vascular Medicine, Department of Medicine, and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
Correspondence to William C. Aird, Beth Israel Deaconess Medical Center, RW-663, Boston MA 02215. E-mail waird{at}bidmc.harvard.edu
| Abstract |
|---|
|
|
|---|
Key Words: endothelium endothelial cells heterogeneity
| Introduction |
|---|
|
|
|---|
| History |
|---|
|
|
|---|
In the 1950s and 1960s, the use of electron microscopy (EM) provided a powerful new window into the endothelium. Early EM studies revealed the presence of characteristic organelles, including plasmalemmal vesicles (which are now called caveolae) and WeibelPalade bodies.1 In addition, these investigations revealedfor the first timethe existence of structural heterogeneity. For example, in some vascular beds, ECs were tightly connected to one another and were surrounded by a continuous basement membrane (continuous endothelium). In a subset of these vascular beds, the ECs were permeated with holes or fenestrae (fenestrated endothelium). A third type of endothelium was characterized by the presence of fenestrae, frank gaps, and a poorly formed underlying basement membrane (discontinuous endothelium). The use of EM, together with tracers, led to revised theories of permselectivity and provided insights into the venular-specific regulation of permeability and leukocyte trafficking. These and other ultrastructural observations led Florey to conclude in 19662:
Now it is recognized that there are many kinds of endothelial cells which differ from one another substantially in structure, and to some extent in function.
The 1970s and 1980s ushered in a new era of cell biology. This was made possible by the first successful isolation and characterization of ECs in culture. In 1973 and 1974, Jaffe and colleagues3 and Gimbrone and colleagues4 independently reported the isolation of human ECs from the umbilical vein. The ability to culture ECs allowed investigators to manipulatein a controlled mannerthe extracellular environment and to study cell biology in far greater detail. Among the seminal findings of that time was the observation that incubation of cultured ECs with inflammatory mediators or bacterial products induced proadhesive, antigen-presenting and procoagulant activities, a phenomenon that was termed "EC activation."511
Although the majority of research groups in the 1980s focused on cultured human umbilical vein ECs (and to a lesser extent, bovine aortic ECs), a small cadre of investigators used immunohistochemistry to characterize the endothelium in vivo. They reported that different vascular beds express different proteins.1214 In other words, the intact endothelium displayed not only ultrastructural diversity, but also molecular heterogeneity. Implicit in these descriptive studies was a criticalif not largely overlookedmessage, which was articulated by Auerbach and colleagues15:
The concept that vascular endothelial cells are not all alike is not a new one to either morphologists of physiologists. Yet laboratory experiments almost always use endothelial cells from large vessels such as the human umbilical vein or the bovine dorsal aorta, since these are easy to obtain and can be readily isolated and grown in culture. The tacit assumption has been that the basic properties of all endothelial cells are similar enough to warrant the use of the cells as in vitro correlates of endothelial cell activities in vivo.
Recognizing the importance of heterogeneity, Auerbach championed the use of cell cultures from multiple organ beds to study the biology of the endothelium. Such an approach would make most sense if vascular bedspecific phenotypes maintained their identity in vitro. As is discussed in a following section (Mechanisms of Endothelial Cell Heterogeneity), this assumption is only partially correct.
| Defining the Endothelium |
|---|
|
|
|---|
|
| Structural Heterogeneity |
|---|
|
|
|---|
ECs possess clathrin-coated pits, clathrin-coated vesicles, multivesicular bodies and lysosomes, which represent the structural components of the endocytotic pathway (reviewed elsewhere34) (Figure 1). Endocytosis targets macromolecules to the lysosomal compartment for degradation. In some cases, endocytosed substances are recycled to the cell surface, or sorted to other subcellular compartments such as the Golgi and endoplasmic reticulum. Endocytosis takes place either by a nonspecific (fluid-phase) process or via receptor-dependent pathways. The latter process is mediated by so-called scavenger receptors, which are responsible for uptake of low-density lipoprotein (LDL), transferrin, albumin, ceruloplasmin, and advanced glycosylation end products. Liver sinusoidal ECs demonstrate particularly high rates of clathrin-mediated endocytosis.
|
In addition to endocytosis, ECs actively engage in transcytosis, which governs the transcellular transfer of molecules across the endothelium. Transcytosis is mediated by specialized structures, including caveolae and vesiculovacuolar organelles (VVOs) (Figure 1). Caveolae are 70-nm membrane-bound, flask-shaped vesicles that usually open to the luminal or abluminal side but are occasionally free in the cytoplasm. Some, but not all, caveolae possess a thin nonmembranous stomatal diaphragm that contains a protein termed plasmalemma protein-1 (PV-1) (also present on fenestral diaphragms).35 Whereas clathrin-coated pits have a thick electron-dense coat, caveolae have a smooth inner surface. With the exception of liver sinusoids, caveolae are more numerous than clathrin coated pits in ECs. The density of caveolae is far greater in capillary endothelium (up to 10 000 per cell) compared with arteries, arterioles, veins, or venules. The number of caveolae is highest in continuous nonfenestrated endothelium, particularly in heart, lung, and skeletal muscle (reviewed elsewhere36). A notable exception is the blood brain barrier, where caveolae are rare.37 In ultrastructural studies of rat capillaries, the fractional area occupied by caveolae was estimated to be 5% in capillaries of the diaphragm, 7.3% in those of the myocardium, 2.5% in those of the pancreas, and 0.8% in those of the jejunal mucosa.38 Although caveolae are present in many non-ECs, there is evidence that expression of caveolin-1, the main structural protein of caveolae, is regulated by distinct transcriptional mechanisms in ECs.39
VVOs, which represent focal collections of membrane-bound vesicles and vacuoles, are most commonly observed in venular endothelium, where the cytoplasm is thicker compared with capillaries (reviewed elsewhere40,41). The complexity of VVOs varies between venules according to the thickness of the endothelium. For example, in skin venules, in which ECs are tall, VVOs occupy nearly one-fifth of the venular endothelial cytoplasm and consist of groups of more than 100 individual vesicles and vacuoles, whereas in the shorter ECs of the mesenteric venules, VVOs consist of smaller aggregates of vesicles. VVOs contain caveolin-1 and are believed to arise from the fusion of individual caveolae.
Two main types of intercellular junctions are recognized in endothelium: tight junctions (also termed zona occludens), which are usually found at the apical region of the intercellular cleft; and adherens junctions (also termed zona adherens) (reviewed elsewhere42,43). Tight junctions form a barrier to transport between ECs (so-called paracellular transport) and help to maintain cell polarity between the luminal and abluminal side of the EC. The junctional composition of intercellular clefts varies across the vascular tree. Large artery ECs display a well developed system of tight junctions, as might be predicted by the conduit function of these vessels and their exposure to high rates of pulsatile blood flow. Within the microvasculature, junctions are tighter in arterioles compared with capillaries and are quite loose in venules. The "disorganized" nature of tight junctions in post-capillary venules likely reflects the role of this blood vessel type in mediating inflammation-induced extravasation of leukocytes and plasma constituents. In contrast, the blood brain barrier, which protects neural tissue from fluctuations in blood composition, is particularly rich in tight functions.
Endothelium may be continuous or discontinuous (Figure 1). Continuous endothelium, in turn, is fenestrated or nonfenestrated. Nonfenestrated continuous endothelium is found in arteries, veins, and capillaries of the brain, skin, heart, and lung. Fenestrated continuous endothelium occurs in locations that are characterized by increased filtration or increased transendothelial transport. These include capillaries of exocrine and endocrine glands, gastric and intestinal mucosa, choroid plexus, glomeruli, and a subpopulation of renal tubules. Fenestrae are transcellular pores (
70 nm in diameter) that extend through the full thickness of the cell. The majority of fenestrae possess a thin 5- to 6-nm nonmembranous diaphragm across their opening. (It was long held that the fenestrae of glomerular ECs lacked a diaphragm; however, more recent evidence suggests that they do indeed possess such a structure.44) With the exception of the glomerulus, fenestral diaphragms contain the integral membrane glycoprotein PV-1.35 The presence of a diaphragm may provide fenestrae with increased size selectivity. Some ECs are polarized with respect to fenestral distribution. For example, in the lamina propria of the human small intestine, capillaries are fenestrated on the side that faces the absorptive epithelial layer of the mucosa.41 The density of fenestrae varies between vascular beds. For example, in rats, fenestral density is almost twice as high in the jejunal versus pancreatic capillaries, accounting for an aggregated area of 9.5% and 6%, respectively, of the total endothelial surface.38
Discontinuous endothelium is found in certain sinusoidal vascular beds, most notably the liver. In contrast to fenestrated continuous endothelium, liver sinusoidal ECs possess larger fenestrations (100 to 200 nm in diameter) that lack a diaphragm and contain gaps (or large circular pores) within individual cells.45 The underlying basement membrane is poorly formed. Fenestrae demonstrate spatial heterogeneity within the liver; they are larger and less frequent in the periportal region compared with the centrilobular region of the liver lobule.46
The thickness of the luminal glycocalyx varies across the vascular tree,47 as does the continuity and thickness of the underlying basement membrane and the degree of investiture with smooth muscle cells or pericytes.
There is increasing evidence that site-specific structural properties are not fixed but, rather, are dynamically regulated during embryogenesis and in the postnatal period. For example, during rodent development blood vessels in the brain are fenestrated and relatively devoid of tight junctions until embryonic day 11 (E11) to E13.48,49 At E10 to E12, liver capillaries in rodents possess a basement membrane and small diaphragm-subtended fenestrae that resemble those in typical fenestrated continuous endothelium. Only later during development (
E17) do these cells begin to acquire the adult phenotype.50 Recent studies suggest that vascular endothelial growth factor (VEGF) plays a key role in the generation and maintenance of fenestrae. For example, in animal and human models, deficiency of VEGF is associated with loss of glomerular fenestrations, increased permeability, and proteinuria.51,52 Similarly, conditional liver-specific knock out of VEGF activity resulted in loss of fenestrae in liver sinusoidal ECs and secondary impairment in lipoprotein clearance.53 Exogenous administration of VEGF has been shown to induce fenestrations in vascular beds, which do not normally have fenestrae, including the capillaries and venules of skin and cremasteric capillaries.54 (In contrast to these latter findings, overexpression of VEGF in the skin of transgenic mice did not induce fenestrations in the subcutaneous vessels.41) The structural properties of the endothelium are also modulated in disease. For example, in a rabbit model of interstitial pulmonary edema, lung capillary ECs demonstrated a 2-fold increase in caveolar density.55 As another example, many liver diseases are associated with defenestration of sinusoidal endothelium and acquisition of a continuous basement membrane.56
| Functional Heterogeneity |
|---|
|
|
|---|
Permeability
The endothelium is semipermeable; it must allow for regulated transport of fluids and solutes into and out of the blood. For purposes of discussion, permeability may be separated into 2 types: basal and inducible (Figure 1).
Under basal conditions, there is a continuous (although physiologically regulatable) flux of material between blood and underlying interstitium. Such activity takes place primarily in the capillaries, the major exchange vessels of the circulation. As noted by Pappenheimer in 195358:
There are good reasons for supposing... that the visible flow of blood through the capillaries is, in fact, very small in comparison with the invisible flow of water and dissolved materials back and forth through the capillary walls...this invisible component of the circulation takes place at a rate which is many times greater than that of the entire cardiac output. Indeed it is by means of this ultramicroscopic circulation through the capillary wall that the circulatory system as a whole fulfills its ultimate function in the transport of materials to and from the cells of the body.
The study of vectorial transport has interested physiologists and electron microscopists alike for decades, and the field has engendered considerable controversy (reviewed elsewhere36,37,59,60). There is now a general consensus that fluids and small solutes move passively across the barrier via the paracellular route, whereas macromolecules use a transcellular route, shuttling across the endothelial barrier in membrane-bound vesicular carriers, including caveolae and VVOs, and/or passing through vesicle-derived transendothelial channels. Transcellular transport of macromolecules may involve receptor-dependent (receptor-mediated transcytosis) or receptor-independent (fluid-phase transcytosis) mechanisms. The importance of caveolae in mediating transcellular transport of albumin was confirmed in studies of caveolin-1/ mice.61
Spatial heterogeneity in basal permeability may be explained by differences in junctional properties, the presence or absence of fenestrae, and/or differential activity of the transcytotic machinery. Indeed, the number and complexity of tight junctions is inversely proportional to permeability. For example, arteries and blood brain barrier have highly developed tight junctions and low permeability. Mice that are null for claudin-5, a major component of the tight junctional region, have selective impairment in blood brain barrier function.62 The importance of adherens junctions in mediating site-specific permeability is evidenced by studies in which the systemic administration of antiVE-cadherin antibodies in mice resulted in preferential changes in vascular permeability in the lung and heart.63 The presence of fenestrae in continuous endothelium is associated with increased permeability of fluids and small solutes, but not macromolecules.64 Although there is a poor correlation between the number of caveolae and segmental permeability, differences in the repertoire of caveolae-associated membrane receptors may underlie site-specific transcytosis.65
In addition to the basal, constitutive transfer of substances across the capillary beds, the endothelium is capable of mediating inducible permeability in states of acute and chronic inflammation. The predominant site of inducible permeability is the postcapillary venule. According to the conventional view, agonists (eg, histamine, serotonin, bradykinin, substance P, and VEGF) induce EC retraction and the formation of intercellular gaps.6668 Others have argued permeability-enhancing agents do not cause gap formation but result in increased transcellular vascular leakage of macromolecules via VVO-derived transendothelial pores.41,69
The predilection for postcapillary venules as a site for inducible permeability may be explained by the relative abundance of VVOs, the relative paucity of tight junctions (hence weak intercellular contacts), and the preferential expression of histamine H2, serotonin, and bradykinin receptors. Whether or not all postcapillary venules in the body share these attributes is unknown. Moreover, inflammation, when severe, may cause barrier dysfunction in other segments of the vascular tree, including large veins, arterioles, and capillaries. For example, tumor necrosis factor (TNF)-
treatment resulted in increased permeability of mouse inferior vena cava, but not the aorta, as measured by accumulation of fluorescein isothiocyanatedextran in the blood vessel wall.70 In EM studies, TNF-
was shown to promote intercellular gap formation in the inferior vena cava.70 In a rat model of diabetes, paracellular permeability was increased first in arterioles and venules, and then in capillaries.71 VEGF has been shown to induce intercellular gaps and fenestra in both postcapillary venules and capillaries.54
Leukocyte Trafficking
Passage of leukocytes from blood to underlying tissue involves a multistep adhesion cascade that includes initial attachment, rolling, arrest and transmigration (Figure 2A). These steps take place almost exclusively in postcapillary venules. Rolling is mediated primarily by interactions between leukocyte carbohydrate-based ligands and endothelial E- and P-selectin, and firm adhesion by interactions between leukocyte integrins and endothelial intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 (reviewed elsewhere7274). The molecular basis of transmigration is less well understood but is believed to involve CD99, PECAM-1/CD31, and junctional adhesion molecule-1 (reviewed elsewhere7274).
|
E-selectin, among the very few genes that is highly restricted to ECs, is expressed in activated, but not "resting" (ie, nonactivated), endothelium (a possible exception is in the bronchial circulation75). In activated endothelium, E-selectin expression is largely confined to postcapillary venules.76,77 In contrast to the usual situation in adult endothelium, E-selectin is not inducible in early embryonic endothelium (before E12.5).78 P-selectin is expressed in megakaryocytes and ECs. In "resting" endothelium, P-selectin is stored intracellularly in preexisting WeibelPalade bodies and is expressed preferentially in postcapillary venules.79 In mice, constitutive expression of cell surface P-selectin is highest in lung and mesentery, compared with heart, brain, stomach, pancreas, intestine, and muscle.80 Systemic administration of histamine in mice resulted in rapid increases in cell surface P-selectin, but not E-selectin, in all tissues examined except the brain.80 Endotoxemia in mice resulted in increased cell surface P-selectin and E-selectin in all tissues examined, including lung and mesentery, heart, brain, stomach, pancreas, intestine, and muscle, with largest increments of both selectins in lung, small intestine, and heart.80 Induction of cell surface P-selectin in multiple tissues was sustained at 24 hours, whereas E-selectin levels had returned to baseline.80 In another study, lipopolysaccharide administration to mice was shown to increase P-selectin mRNA expression 87-fold in the heart, 12-fold in the lung, 15-fold in the liver, 12-fold in kidney, 33-fold in brain, and 2.5-fold in the spleen.77 In contrast, E-selectin was induced 14.6-, 5.6-, 3.8-, 18-, 5.3-, and 0.6-fold, respectively.77 Cecal ligation puncture in mice resulted in increased P-selectin protein expression in brain, kidney, stomach, small bowel, and large bowel, an effect that was greatly accentuated in obese animals.81 In a mouse model of sickle cell disease, constitutive expression of P-selectin was increased in several tissues, whereas E-selectin was increased in only the penis.82 Interestingly, inflammatory mediators such as interleukin-1 and TNF-
induce P-selectin mRNA expression in mice, but not primates,83 underscoring the importance of interspecies differences in transcriptional control.
Unlike E-selectin and P-selectin, ICAM-1 and VCAM-1 are expressed in many vascular and nonvascular cell types. Constitutive expression of cell surface VCAM-1 in mice is generally lower than that of ICAM-1, with the exception of the heart, where both are equally expressed; and the brain, where VCAM-1 density is 4-fold higher than that of ICAM-1.84 In normal mice and rabbits, ECs at sites predisposed to atherosclerosis express ICAM-1 and VCAM-1.85 Both ICAM-1 and VCAM-1 are induced by activation agonists. For example, in mice administered lipopolysaccharide, cell surface expression of ICAM-1 and VCAM-1 was increased in heart and small intestine (ICAM-1 was also induced in mesentery and brain) at 5 hours, with highest induction of ICAM-1 occurring in heart, and VCAM-1 in small intestine (VCAM-1 levels were actually reduced in the spleen).86 In another study of mouse endotoxemia, ICAM-1 mRNA expression was induced 6-fold in the heart, 1.9-fold in the lung, 2.2-fold in the liver, 18.3-fold in kidney, 6.8-fold in brain, and 2.1-fold in the spleen.77 In the same report, VCAM-1 was induced 2.0-, 1.1-, 0.6-, 1.3-, 2.1-, and 0.6, respectively. In contrast to P-selectin and E-selectin, which were localized to postcapillary venules, VCAM-1 and ICAM-1 were also induced in the capillaries of the heart.77 In a cecal ligation puncture model of sepsis, ICAM-1 protein was induced in lung, kidney, liver, and heart, whereas VCAM-1 levels were induced in kidney, liver, and heart, but not lung.87
There are 2 routes for leukocytes to pass through the endothelium. They may pass between ECs (the paracellular route), or they may pass through the EC itself (the transcellular route). Recent studies have provided compelling evidence that leukocytes may indeed transmigrate through ECs.41,88,89 An interesting question is whether different vascular beds use different rates of paracellular versus transcellular transport, and/or whether this ratio differs with different subsets of leukocytes or different activation agonists. For example, it is tempting to speculate that the bloodbrain barrierwith its abundance of tight junctional complexesrelies primarily on the transcellular route (as it does for solute and fluid transport).
Although leukocyteendothelial interactions are generally observed in postcapillary venules, they may also occur in other segments of the vascular tree, including large veins, capillaries, and arterioles. For example, perivascular exposure of mouse inferior vena cava to TNF-
in vivo resulted in the induction of ICAM-1, VCAM-1, E-selectin, and P-selectin.70 This pattern was similar to that observed in postcapillary venules and was more pronounced compared with the aorta and iliac arteries. Moreover, the increased cell adhesion molecule expression in TNF-
treated inferior vena cavae correlated with increased firm adhesion of leukocytes. Data suggest that leukocyte sequestration and transmigration in the pulmonary circulation occurs primarily in alveolar capillaries (reviewed elsewhere90,91) (Figure 2B). The mechanism involves trapping of poorly deformed activated leukocytes on activated endothelium (reviewed elsewhere92). In liver inflammation, the sinusoidal endothelium accounts for 70% to 80% of leukocyte adhesion.93 Previous studies have shown that certain mediators, such as TNF-
, interleukin-1, cigarette smoke, and oxidized LDL, induce leukocyte rolling in arterioles and arteries.9497 Inflamed arterial endothelium may support transmigration of different subsets of leukocytes, compared with postcapillary venules. For example, systemic administration of angiotensin II to rats resulted in increased adherence and transmigration of lymphocytes and monocytes in arterioles, and of neutrophils in postcapillary venules.98
Just as leukocyte trafficking does not always take place in postcapillary venules, the multistep cascade does not apply universally to all vascular beds. For example, in the lung and the liver, leukocytes adhere to capillary endothelium independent of a rolling motion93 (Figure 2B and 2C). Neutrophil recruitment in these vascular segments does not require E- or P-selectin but is partially dependent on ICAM-1 (arguing against a role for simple trapping of white blood cells).93,99,100 Together, these data strongly suggest that the universal cascade, although perhaps relevant to the microvasculature of those tissues in which the majority of studies have been performed, does not apply to all organs or vascular beds.
Another form of leukocyte trafficking, which is distinct from those described above, takes place in secondary lymphoid organs, including peripheral lymph nodes, mesenteric lymph nodes, Peyers patches, appendix, and tonsils. Here, lymphocytes transmigrate across specialized postcapillary venules, termed high endothelial venules (HEVs) (reviewed elsewhere25,26,101). In contrast to nonlymphoid postcapillary venules, which mediate appreciable levels of leukocyte transmigration only during inflammation, HEVs support the constitutive recirculation of lymphocytes between blood and lymph nodes (Figure 2D). Endothelial cells lining HEVs are morphologically distinct and express a unique repertoire of adhesion molecules. Lymphocyte homing in peripheral lymph nodes depends on three distinct molecular steps: (1) rolling, mediated by interactions between lymphocyte L-selectin and its ligand on HEV ECs, namely peripheral node addressin (PNAd); (2) chemokine-mediated activation of lymphocyte integrins (eg, constitutively expressed CCL21 on HEV ECs binds to CCR7 on lymphocytes, resulting in activation of lymphocyte function-associated antigen (LFA)-1; and (3) firm adhesion, mediated by lymphocyte LFA-1. The fact that neutrophils express L-selectin and LFA-1, but not CCR7, may explain why granulocytes roll but do not arrest (or transmigrate) in HEVs. In mesenteric lymph nodes, ECs lining HEVs express not only PNAd but also the mucosal addressin cell adhesion molecule-1, which binds to
4ß7 on the surface of lymphocytes.
The extent to which differential expression of selectins and other adhesion molecules can be translated into regional differences in the regulation of leukocyte adhesion and transmigration is presently unknown. Clearly, many factors are involved in regulating leukocyte trafficking in space and time. Thus, at present, it is more instructive to consider the remarkable heterogeneity in molecular profiles and site-specific endothelialleukocyte interactions than it is to infer precise causeeffect relationships between them.
Hemostasis
A common function of the endothelium is to maintain blood in a fluid state, and to promote limited clot formation when there is a breech in the integrity of the vascular wall. On the anticoagulant side, ECs express tissue factor pathway inhibitor (TFPI), heparan, thrombomodulin, endothelial protein C receptor (EPCR), tissue-type plasminogen activator (t-PA), ecto-ADPase, prostacyclin, and nitric oxide. On the procoagulant side, ECs synthesize tissue factor, plasminogen activator inhibitor (PAI)-1, von Willebrand factor (vWF), and protease activated receptors (reviewed elsewhere102). Importantly, endothelial-derived anticoagulant and procoagulant molecules are unevenly distributed throughout the vasculature (reviewed elsewhere22,102) (Figure 3).
|
EPCR is expressed predominantly in large arteries and veins,103 whereas thrombomodulin is highly expressed in blood vessel types of every caliber in all organs, with the exception of the brain, where levels are low.104 In mice, EPCR transcripts are highest in the placenta, lung, liver, and heart.105 Expression of EPCR and/or thrombomodulin is decreased in some but not all models of inflammation. For example, endotoxemia resulted in reduced thrombomodulin expression in rat liver sinusoidal ECs.106 In patients with meningococcemia, thrombomodulin and EPCR protein levels were decreased in the endothelial lining of dermal microvessels.107 However, in rats injected with Escherichia coli, there were no changes in thrombomodulin antigen levels or activity.108 Moreover, in a baboon model of E coli sepsis, thrombomodulin protein levels were unaltered.109 In mice, systemic administration of lipopolysaccharide, but not TNF-
, resulted in increased EPCR mRNA expression in lung and heart, with protein expression still limited to large vessel endothelium.105 In humans, thrombomodulin and EPCR were shown to be downregulated in atherosclerotic coronary arteries.110
vWF is expressed predominantly on the venous side of the circulation.102,111 In mice, basal vWF expression mRNA was reported to be highest in lung and lowest in liver and muscle.111 In en face Hautchen preparations of rat aorta, only 20% to 50% of ECs were shown to be positive for vWF as detected by immunohistochemistry.112 vWF positivity occurred in groups of cells orientated along the longitudinal axis of the aorta but was scant at sites of intercostal orifices.112 Systemic administration of lipopolysaccharide in mice resulted in upregulation of vWF mRNA in heart and kidney but decreased expression in the lung, aorta, brain, and adipose tissue.111
In mice, t-PA expression in the endothelium was reported to be restricted to arteries of the pulmonary system and central nervous system.113 As mice reached maturity, expression of t-PA in the brain decreased in large arteries, yet persisted in smaller vessels.113 PAI-1 expression in mice is highest in lung, followed by heart, brain, spleen, liver, and kidney.77 Endotoxemia resulted in 187-fold increase in PAI-1 in the liver but only a 3-fold increase in spleen.
TFPI expression in human tissues is highest in placenta and lung and lowest in the brain.114 In the mouse, TFPI mRNA expression is highest in lung and undetectable in liver.115 Under normal conditions, TFPI is expressed primarily by microvascular endothelium.114,116 Tissue factor is not detectable in normal intact endothelium. However, tissue factor is expressed by ECs in certain pathophysiological states. For example, in a baboon model of E coli sepsis, the gene was upregulated in a subset of ECs in the marginal zone of splenic follicles109 and in regions of disturbed flow in the aorta.28 Tissue factor was also detected in pulmonary vein endothelium in a mouse model of sickle cell disease.117 Human atherosclerotic coronary arteries demonstrate increased tissue factor and TFPI levels, which colocalize in ECs.118 TFPI protein and mRNA expression and TFPI activity were shown to be increased in the ECs overlying plaque in human atherosclerotic carotid arteries.119 Tissue factor has also been detected in ECs in tumors (reviewed elsewhere120), and in xenograft and allograft vasculopathy.121,122
The differential distribution of procoagulants and anticoagulants in the endothelium suggests that ECs from different sites of the vascular tree use site-specific "formulas" of procoagulants and anticoagulants to balance local hemostasis.
In humans and animal models, systemic imbalance of clotting factors results in a local thrombotic phenotype (reviewed elsewhere123). For example, factor V Leiden is associated with an increased risk for venous thromboembolism but not acute myocardial infarction or stroke.124,125 A similar propensity for thrombosis on the venous side of the circulation was demonstrated in mice that carry the factor V Leiden gene.126 Mice with antithrombin III (ATIII) deficiency develop hepatic and cardiac thrombosis and die by E16.5.127 Interestingly, when ATIII/ were crossed with genetically modified mice that express low levels of tissue factor, thrombosis was attenuated in the heart, but not the liver.128 As a final example of organ-specific thrombosis, mice with low functional levels of thrombomodulin reveal increased fibrin deposition in the lung, heart, spleen, and liver but not brain or kidney.129 Taken together, these studies provide indirect, yet compelling, evidence that systemic imbalances in natural anticoagulant activity may be "channeled" by the endothelium into local thrombotic phenotypes.
It is well established that different vascular beds express distinct repertoires of anticoagulants and procoagulants. Moreover, it is widely accepted that systemic imbalances in hemostatic factors lead to site-specific thrombus formation. However, despite significant advances in these areas, it is difficult to predict thrombotic phenotypes based solely on our knowledge of vascular bedspecific profiles of hemostatic factors. Rather, the dual approach of characterizing the clinical phenotype of hypercoagulable states in humans and mice, while continuing to finely map the patterns of basal and inducible hemostatic gene expression, provides an invaluable tool for further delineating mechanisms of vascular bed-specific hemostasis.
| Documenting Endothelial Cell Phenotypes |
|---|
|
|
|---|
A popularalthough far less physiologicalstrategy for documenting EC heterogeneity is to study cultured ECs harvested from different vascular beds. Such an approach has been used to assay for differences in gene or protein expression, enzyme activity, or signaling pathways.145153 Additional studies have examined the differential effects of 1 or more agonists on different types of ECs.154159 These in vitro analyses, although interesting and potentially important, must be interpreted with caution. As discussed below, ECs when removed from their native microenvironment are uncoupled from critical extracellular cues and undergo phenotypic drift. (In one study, 40% of proteins expressed in lung endothelium in vivo were not detected in vitro.140) Thus, the extent to which site-specific differences in vitro correlate with those in the intact endothelium is unclear, emphasizing the importance of validating these results in vivo.
One approach for approximating in vivo conditions, while maintaining the advantages of cell culture, is to recapitulate the microenvironment in vitro. For example, ECs may be grown in coculture with 1 or more non-EC types, allowing varying degrees of heterotypic cellcell contact.160163 Alternatively, ECs may be incubated with plasma/serum from patients or animal models,77,164 or medium that is conditioned during culture with another cell type. Culturing ECs under flow is a more physiological approach compared with static conditions. A major advance in this area is the adjustment of hemodynamic parameters in vitro to approximate in vivo flow patterns.165
| Mechanisms of Endothelial Cell Heterogeneity |
|---|
|
|
|---|
In theory, spatial and temporal differences in the extracellular environment are sufficient to explain the existence of structural and functional heterogeneity of the endothelium. However, there is also evidence that certain site-specific properties of ECs are epigenetically programmed, such that their maintenance is no longer dependent on signals from the extracellular milieu (Figure 4). For example, DNA microarray studies of multiply passaged ECs cultured from different sites of the human vasculature revealed differences in transcriptional profiles between arterial and venous ECs, and between macrovascular and microvascular ECs.152 Although the data were not systematically validated in vivo, the shear number and reproducibility of these differences provide compelling evidence for the existence of site-specific epigenetic modification. Stimulation of human coronary artery ECs with oxidized LDL resulted in more pronounced changes in the expression of genes associated with adhesion, proliferation, and apoptosis pathways compared with human saphenous vein ECs, suggesting an inherent susceptibility of arterial versus venous ECs to atherosclerosis.166 Pulmonary artery and microvascular ECs display site-specific barrier properties that are preserved in multiply passaged cells.167
|
In a particularly revealing study, Lacorre et al harvested human ECs from HEVs of tonsils and umbilical veins and compared gene expression profiles in freshly isolated cells (as a surrogate for in situ endothelium) and cells grown in culture for 2 days.139 They showed that some, but not all, site-specific transcripts were downregulated between the time of harvest and after 2 days of culture. These latter findings provide strong support for the dual role of microenvironment and epigenetics in mediating vascular bedspecific phenotypes.
Several mechanisms have been implicated in epigenetic modification including DNA methylation, methylation of histone proteins, and histone hyperactivation (reviewed elsewhere168). Methylation of DNA and histones is regulated by a balance between methylases and demethylases, whereas acetylation of histones is mediated by a balance between histone acetyltransferases and histone deacetylases. Recent in vitro studies have demonstrated a potential role for DNA methylation and/or histone acetylation/methylation in mediating EC-specific gene expression.169172 However, the extent to which epigenetic modification mediates vascular bed-specific phenotypes (ie, EC heterogeneity) is currently unknown and is an area that is ripe for study.
It is interesting to speculate that aging and/or disease is associated with increased epigenetic modification, hence less plasticity of the endothelium. For example, human intestinal microvascular ECs isolated from affected regions in inflammatory bowel disease demonstrate hyperadhesiveness to leukocytes compared with cells isolated from unaffected regions, or from patients without inflammatory bowel disease.173 Remarkably, these differential properties, which were attributed to differences in inducible nitric oxide synthase activity, persisted during sequential passaging.174
In addition to proximate mechanisms, biological traits (such as EC heterogeneity) require evolutionary explanations. Specifically, what is the phylogeny of the trait and how does it provide a fitness advantage? Endothelium is absent in invertebrates, cephalochordates, and tunicates, but present in the 3 major groups of extant vertebrates, including hagfish, lampreys, and jawed vertebrates. These observations predict that the endothelium evolved in a common ancestor of all extant vertebrates following the divergence of cephalochordates and tunicates (ie, between 540 and 510 million years ago). A recent study of hagfish endothelium revealed the existence of EC heterogeneity in structure, molecular markers, and function.175 These data suggest that EC heterogeneity evolved as an early, perhaps obligate, feature of this cell lineage. Phenotypic heterogeneity is likely to provide at least 2 fitness advantages: (1) it allows the endothelium to conform to the diverse needs of the underlying tissues throughout the body; and (2) it provides the endothelium with the capacity to adapt to different microenvironments (eg, the profoundly hypoxic and hyperosmolar environment of the inner medulla of the kidney versus the well-oxygenated environment of pulmonary alveoli).
| Implications for Diagnosis and Therapy |
|---|
|
|
|---|
The endothelium is rapidly and preferentially exposed to systemically delivered agents. Given the capacity of ECs to sense and respond to the local environment, it is hard to imagine that there exists any treatment for any disease that does not affect EC phenotypes in one way or another. From a therapeutic standpoint, the combination of phenotypic heterogeneity and modulability offers both opportunities and challenges. On one hand, the identification and characterization of vascular bed-specific "zip codes" should provide a foundation for site-specific targeting. On the other hand, drugs that lack such specificity are likely to exert mixed effects on the vasculaturewith protective effects in some vascular beds and neutral or deleterious consequences in others. This idea is supported by the many knockout models (some of which have been detailed in the current review) that demonstrate vascular bedspecific phenotypes. In so far as treatment against one or another target creates a functional knock out of that target, the effects on the vasculature will be similarly heterogeneous. For example, a treatment aimed toward neutralizing P-selectin might reduce leukocyte trafficking in the gastrointestinal tract, but not the liver. A drug that is designed to promote refenestration in liver disease might also induce fenestrations (hence permeability) in vascular beds such as blood brain barrier, with potentially disastrous consequences.
| Revisiting the Definition of the Endothelium |
|---|
|
|
|---|
| Conclusions |
|---|
|
< |
|---|